Biotech Startups

Biogenera develops BGA002, an anti-tumor therapeutic candidate targeting neuroblastoma and rhabdomyosarcoma, which primarily affect children and adolescents. The company is advancing the drug through clinical development with a structured regulatory pathway in Europe.

1 investor

Biograil is a company backed by venture capital investors specializing in deep tech, sustainable technologies, and life sciences ventures across Europe.

1 investor

A community biotechnology laboratory in Ecuador that democratizes access to life sciences education and research. It provides training, workspace, and support for students and entrepreneurs interested in biotechnology and experimental sciences.

1 investor

Imviva is a clinical-stage biotechnology company developing allogeneic CAR-T cell therapies for oncology and autoimmune diseases. The company focuses on creating safer, more effective off-the-shelf cell therapies designed to improve patient access and outcomes in regenerative medicine.

1 investor

BioHive is an organization supporting Utah's life sciences industry, coordinating community, communications, and returnship programs for the sector. It operates in the state of Utah, United States.

1 investor

BioImagene sells chemical compounds and reference standards, primarily for research and analytical purposes.

1 investor

Biointaxis is an academic biotech spin-off developing a gene therapy to restore the function of a defective protein in patients with Friedreich's ataxia, a rare inherited neurodegenerative disease. The company handles early-stage R&D, pre-clinical, and early clinical (Phase I/II) development, aiming to license production and distribution rights to pharmaceutical partners.

1 investor

Unable to determine company business from page content. The page appears to be an investor relations contact page in Chinese for a company with headquarters in Shenzhen.

1 investor

BioKier develops oral products for managing lipids and glucose in type 2 diabetes and cardiometabolic disorders, designed to replicate the metabolic benefits of bariatric surgery through colon-targeted nutrient delivery. The company is a clinical-stage biotech pursuing regulatory approval via the 505(b)2 NDA pathway.

1 investor

BioKine develops immunotherapy drug candidates targeting cancer metastasis and treatment resistance, with its lead product BL-8040 in multiple clinical trials including stem cell mobilization, acute myeloid leukemia, and pancreatic carcinoma.

1 investor

Biokorf works on 3D Integrated Pharmaceuticals, including particle engineering and cocrystals for drug development.

1 investor

BioLamina develops full-length human recombinant laminin proteins and related cell culture substrates for research and clinical applications. The company's products support the growth and differentiation of pluripotent stem cells, tissue-specific cells, and organoid development in both 2D and 3D culture environments.

1 investor

BioLife Solutions develops biopreservation media, cryopreservation tools, storage systems, and closed-system cell processing solutions for cell and gene therapy manufacturing. It serves bioprocess engineers, therapy developers, and contract development and manufacturing organizations (CDMOs), with regulatory support for GMP, FDA, and EMA compliance.

1 investor

Biolinco provides a platform for cell line development that uses DNA barcoding and multi-omic characterization to help biopharmaceutical companies evaluate and select optimal cell clones. The platform addresses limitations in traditional workflows that evaluate only a small number of clones.

1 investor

BioLink is a biotechnology company that develops and manufactures process equipment and consumables for life science applications, including recombinant protein drugs, vaccines, antibody drugs, cell therapy, and gene therapy production. The company supplies upstream cell culture, disposable storage and downstream chromatography, filtration, and hydration products along with process development services.

1 investor

BioLM provides AI/ML solutions for protein and DNA analysis, serving researchers and scientists in the biotechnology and synthetic biology sectors with tailored models and APIs.

1 investor

Biologic Input Output Systems develops neural interface technology to restore natural movement and sensation for individuals with limb loss, enabling intuitive control of prosthetic limbs through direct brain-machine connections.

1 investor

Biologos is a GMP-certified manufacturer of custom cell culture media, buffers, and reagents for biopharmaceutical and research customers. The company specializes in rapid formulation and aseptic manufacturing of biologics-related products to support disease treatment and prevention efforts.

1 investor

Biolumen is a biotech company focused on bioengineering for wellness, founded by a serial entrepreneur with expertise in biopolymers. The company appears to be developing food and beverage-related products leveraging bioengineering innovations.

1 investor

Biolyst supplies tools, products, and consulting services to clinicians and research scientists advancing discovery in the life sciences. The company specializes in supporting laboratory and clinical workflows through comprehensive product portfolios and strategic partnerships with healthcare and research institutions.

1 investor

Biolytx Pharmaceuticals is developing a novel antibiotic peptide, currently in pre-clinical trials, to treat serious hospital-acquired infections including those resistant to existing antibiotics. It operates in the biotechnology and pharmaceutical drug development sector.

1 investor

Biomakers operates a precision oncology platform that combines genomic testing, clinical data, biobanking, and AI to support cancer care and drug and diagnostic development. It focuses on expanding access to cancer care across Latin America while generating clinical and biospecimen data.

1 investor

Biomarx develops automated liquid biopsy diagnostics using biosensing technologies for early cancer and disease detection, delivering test results in under two hours at low cost. Its products target clinicians and healthcare providers seeking rapid, affordable precision diagnostics for personalised medicine.

1 investor

1 investor